Three New Regions on Chromosome 17p13.3 Distal to P53 with Possible Tumor Suppressor Gene Involvement in Lung Cancer

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 2000 Jun 30

PMID 10874210

Citations 5

Authors

E Tsuchiya

A Tanigami

Y Ishikawa

K Nishida

M Hayashi

Y Tokuchi

T Hashimoto

S Okumura

S Tsuchiya

K Nakagawa

Affiliations

Soon will be listed here.

Abstract

We investigated loss of heterozygosity (LOH) at the distal portion of the p53 gene on the short arm of chromosome 17 in lung cancers in order to search for new tumor suppressor genes. The roles of the putative genes were also studied in terms of pathological features. One hundred and forty-five resected non-small cell lung cancers were examined for LOH using 11 markers mapped on, and distal to the p53 locus, and deletion maps were constructed. Four commonly deleted regions were found: one from TP53 to ENO3, where the p53 gene resides, and three others from ENO3 to D17S1566, D17S379 to D17S1574 and distal to ABR, with LOH frequencies almost the same as, or higher than, at the TP53 locus. Examination of the relationship between LOH of the latter three regions and histopathological parameters of adenocarcinomas (genetically negative for p53 mutation) revealed allelic losses on D17S379 to be associated with advanced lesions, while D17S513 was more frequently deleted in poorly differentiated tumors. These results indicate that new tumor suppressor gene(s) may reside on these three distinctly deleted regions on chromosome 17p13.3 distal to the p53 gene in lung cancer, with possible roles in progression and differentiation of adenocarcinomas.

Citing Articles

Genetic Alterations of in Solid Tumors Using Integrative Multi-Platform Analysis.

Olivera Santana B, de Loyola M, Gualberto A, Pittella-Silva F Int J Mol Sci. 2024; 25(11).

PMID: 38892284 PMC: 11172816. DOI: 10.3390/ijms25116097.

Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma.

Wang Y, Zhang C, Ji C, Jin W, He X, Yu S Front Genet. 2022; 13:1006938.

PMID: 36313439 PMC: 9597639. DOI: 10.3389/fgene.2022.1006938.

Expression and clinical significance of HCCS1 in non-small cell lung cancer.

Xiao-Yong S, Zhi-Feng L, Fan-Zhen L, Zhen R, Jian Z, Hai-Long H Contemp Oncol (Pozn). 2013; 16(4):328-31.

PMID: 23788903 PMC: 3687437. DOI: 10.5114/wo.2012.30062.

Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer.

Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, Naito K Br J Cancer. 2004; 91(6):1025-31.

PMID: 15292937 PMC: 2747707. DOI: 10.1038/sj.bjc.6602073.

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004.

PMID: 14973191 PMC: 365734. DOI: 10.1073/pnas.0307323101.

References

Greenblatt M, BENNETT W, Hollstein M, Harris C . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18):4855-78. View

Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S . MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997; 75(9):1302-8. PMC: 2228229. DOI: 10.1038/bjc.1997.221. View

Wales M, Biel M, El Deiry W, Nelkin B, Issa J, Cavenee W . p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995; 1(6):570-7. DOI: 10.1038/nm0695-570. View

Esposito V, Baldi A, De Luca A, Groger A, Loda M, GIORDANO G . Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997; 57(16):3381-5. View

Sato S, Nakamura Y, Tsuchiya E . Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1994; 54(21):5652-5. View

Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y . Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun. 1994; 202(3):1426-30. DOI: 10.1006/bbrc.1994.2090. View

Schultz D, Vanderveer L, Berman D, Hamilton T, Wong A, Godwin A . Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res. 1996; 56(9):1997-2002. View

Konishi H, Kozaki K, Yatabe Y, Mitsudomi T, Fujii Y, Sugiura T . Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene. 1998; 17(16):2095-100. DOI: 10.1038/sj.onc.1202128. View

Harbour J, Lai S, Whang-Peng J, Gazdar A, Minna J, Kaye F . Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241(4863):353-7. PMC: 5480895. DOI: 10.1126/science.2838909. View

10.

Meroni G, Reymond A, Alcalay M, Borsani G, Tanigami A, Tonlorenzi R . Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor. EMBO J. 1997; 16(10):2892-906. PMC: 1169897. DOI: 10.1093/emboj/16.10.2892. View

11.

Biegel J, Burk C, Barr F, Emanuel B . Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res. 1992; 52(12):3391-5. View

12.

Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T . Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 1987; 84(24):9252-6. PMC: 299731. DOI: 10.1073/pnas.84.24.9252. View

13.

Apolinario R, van der Valk P, de Jong J, Deville W, Dingemans A, van Mourik J . Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997; 15(6):2456-66. DOI: 10.1200/JCO.1997.15.6.2456. View

14.

Strauss G, Kwiatkowski D, Harpole D, Lynch T, SKARIN A, Sugarbaker D . Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol. 1995; 13(5):1265-79. DOI: 10.1200/JCO.1995.13.5.1265. View

15.

Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inazawa J . Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer. 1994; 9(3):173-9. DOI: 10.1002/gcc.2870090305. View

16.

Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F . Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol. 1997; 28(2):233-7. DOI: 10.1016/s0046-8177(97)90112-x. View

17.

Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S . p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 1999; 59(21):5572-7. View

18.

Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M . p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246(4929):491-4. DOI: 10.1126/science.2554494. View

19.

Yokoyama S, Yamakawa K, Tsuchiya E, Murata M, Sakiyama S, Nakamura Y . Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1992; 52(4):873-7. View

20.

Morris C, Benjes S, Haataja L, Ledbetter D, Heisterkamp N, Groffen J . Spatial organization of ABR and CRK genes on human chromosome band 17p13.3. Oncogene. 1995; 10(5):1009-11. View